The University of Edinburgh has revealed annual commercialisation figures showing strong investment in spinouts, and a majority of new companies formed to harness data and AI for public good.
Biopharmaceutical spinout Resolution Therapeutics has announced the first patient has been dosed and safety cleared in the Phase I/II EMERALD study of its novel therapy for end-stage liver disease.
The role of government is important, but universities also need to back their founders. This means funding, training and culture change, write Professors Damian Mole and Scott Webster, founders of spinout Kynos Therapeutics, and Dr Andrea Taylor, CEO of Edinburgh Innovations
Edinburgh Innovations has announced record research translation figures for the financial year 2023/24, including the launch of 127 companies, 140 patents filed and £141 million invested into University-associated companies.
Biotech spinout Resolution Therapeutics has announced it has raised £63.5 million in a series B financing round led by healthcare investor Syncona Ltd.
A clinical trial follow-up featuring patients with end-stage liver cirrhosis shows increased survival rates and fewer liver transplants in those treated with macrophage cell therapy.
The University’s groundbreaking work in emerging engineering biology and AI-led approaches to future health was showcased recently in Boston, USA.
A new type of cell therapy to treat patients with liver scarring, or cirrhosis, shows promise of being the first medical treatment for this common and lethal condition.
At the University of Edinburgh it is policy to promote the commercial potential of any new ideas, discoveries or inventions arising from research, and there is an established commercialisation process for transferring them to industry through Edinburgh Innovations (EI).
Here in Scotland, we currently have a confluence of factors – data capacity, clinical and academic expertise, and technology – that put us in pole position to translate our excellent liver disease research and to develop the innovative new treatments we need, writes Dr Prakash Ramachandran, MRC Senior Clinical Fellow and Consultant Hepatologist at the University of Edinburgh...
The Mass Spectrometry Core is a facility equipped with state-of-the-art instrumentation for sample preparation, chromatographic separation and mass spectrometry analysis for small molecule quantitation of biomarkers and drugs.
